Citations

Clear

3042 citation(s) found for "Kumar, S".

Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group
Mahadevan, Uma , Bernasko, Nana, Boland, Brigid S. , Dubinsky, Marla C. , Friedman, Sonia , Kane, Sunanda V. , Manthey, Jacob, Sauberan, Jason , Robinson, Christopher James , Chambers, Christina , Stone, James L. , Jain, Rajeev Kumar , Friedman, Sonia

Mayo Clinic

Inflammatory Bowel Diseases | March 1, 2019 | Volume: 25 | Issue: 4 | Pages: 627-641

10.1093/ibd/izz037 | PMID 30821832 Get It

Ultrasound Radiation Force for the Assessment of Bone Fracture Healing in Children: An In Vivo Pilot Study
Ghavami, Siavash , Gregory, Adriana , Webb, Jeremy, Bayat, Mahdi , Denis, Max , Milbrand, Todd A., Larson, A. Noelle , Fatemi, Mostafa , Alizad, Azra , Kumar, Viksit, Larson, A Noelle , Alizad, Azra , Fatemi, Mostafa , Kumar, Viksit

Mayo Clinic

Sensors | February 25, 2019 | Volume: 19 | Issue: 4 | Pages: 955

10.3390/s19040955 | PMID 30813465 Get It

Vibrational characteristics of bone are directly dependent on its physical properties. In this study, a vibrational method for bone evaluation is introduced. We propose a new type of quantitative vibro-acoustic method based on the acoustic radiation force of ultrasound for bone characterization in persons with fracture. Using this method, we excited the clavicle or ulna by an ultrasound radiation force pulse which induces vibrations in the bone, resulting in an acoustic wave that is measured by a hydrophone placed on the skin. The acoustic signals were used for wave velocity estimation based on a cross-correlation technique. To further separate different vibration characteristics, we adopted a variational mode decomposition technique to decompose the received signal into an ensemble of band-limited intrinsic mode functions, allowing analysis of the acoustic signals by their constitutive components. This prospective study included 15 patients: 12 with clavicle fractures and three with ulna fractures. Contralateral intact bones were used as controls. Statistical analysis demonstrated that fractured bones can be differentiated from intact ones with a detection probability of 80%. Additionally, we introduce a “healing factor” to quantify the bone healing progress which successfully tracked the progress of healing in 80% of the clavicle fractures in the study.
Acoustic navigation of intramyocardial injection needle catheter using color doppler echocardiography
Katayama, Minako , Zarbatany, David, Vaitkus, Veronica V. , Fortuin, David, Fatemi, Mostafa , Bëlohlávek, Marek , Fatemi, Mostafa , Kumar, Viksit

Mayo Clinic

2018 IEEE International Ultrasonics Symposium (IUS) | February 21, 2019 | Volume: No volume available | Issue: No issue available | Pages: 1-3

10.1109/ultsym.2018.8579717 Get It

Temporal trends of survival and utilization of mechanical circulatory support devices in patients with in‐hospital cardiac arrest secondary to ventricular tachycardia/ventricular fibrillation
Patel, Nileshkumar, Kumar, Varun , Panakos, Andrew, Narayanan, Mahesh Anantha , Bhardwaj, Bhaskar , Arora, Shilpkumar , Deshmukh, Abhishek , Patel, Nileshkumar , Basir, Mir B. , Cohen, Mauricio G. , Kini, Annapoorna , Sharma, Samin K. , Dangas, George , O’Neill, William W. , Alfonso, Carlos E., Patel, Nileshkumar J , Atti, Varunsiri , Kumar, Varun , Anantha Narayanan, Mahesh , Patel, Nish , Basir, Mir B , Cohen, Mauricio G , Kini, Annapoorna S , Sharma, Samin K , Dangas, George

Mayo Clinic

Catheterization and Cardiovascular Interventions | February 21, 2019 | Volume: 94 | Issue: 4 | Pages: 578-587

10.1002/ccd.28138 | PMID 30790415 Get It

AbstractBackgroundPulseless ventricular tachycardia/ventricular fibrillation (VT/VF) is the initial rhythm in a third of in‐hospital cardiac arrest patients. Mechanical circulatory support (MCS) device use remains poorly understood in this population.MethodsWe conducted an observational analysis of temporal trends in the utilization of MCS in VT/VF IHCA between January 2008 and December 2014 utilizing the Nationwide Inpatient Sample (NIS) database. Using multivariable analysis, we assessed factors associated with MCS use and survival to discharge.ResultsAmong 151,628 hospitalizations with VT/VF IHCA, 14,981 (9.9%) received MCS. Intra‐aortic balloon pump (IABP) was the most commonly used MCS (9.1%). From 2008 to 2014, there was significant increase in the utilization of MCS (8.7–11%; ptrend < 0.0001). On multivariable analysis, there was 12‐fold increase and three‐fold increase in the utilization of PVAD and ECMO respectively; however, there was no significant change in the use of IABP. Over the seven‐year sample period, there was significant increase in the overall survival to hospital discharge (35.4–43.5%; ptrend < 0.0001). Survival to hospital discharge increased in both MCS and non‐MCS groups.ConclusionThere was significant increase in utilization of MCS after VT/VF IHCA during the study period. IABP was the most commonly utilized MCS. The survival to hospital discharge increased in the overall study population including both MCS and non‐MCS groups. Future studies are needed to identify patient population most likely to benefit from the use of MCS after VT/VF IHCA.
Breast Cancer, Version 3.2018
Gradishar, William J. , Anderson, Benjamin O. , Abraham, Jame , Aft, Rebecca , Allison, Kimberly H. , Blair, Sarah L. , Burstein, Harold J. , Dang, Chau T. , Farrar, William B., Goldstein, Lori J. , Isakoff, Steven J. , Lyons, Janice A., Moran, Meena S. , O'Regan, Ruth M., Patel, Sameer A. , Pierce, Lori J. , Reed, Elizabeth , Sitapati, Amy M. , Smith, Mary Lou , Telli, Melinda L. , Shead, Dorothy A. , Goetz, Matthew P. , Elias, Anthony , Giordano, Sharon H. , Marcom, Paul Kelly , Mayer, Ingrid A. , Mortimer, Joanne , Rugo, Hope S. , Smith, Karen L. , Soliman, Hatem Hussein , Ward, John Headley , Young, Jessica S. , Kumar, Rashmi , Telli, Melinda L

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 20, 2019 | Volume: 17 | Issue: 2 | Pages: 118-126

10.6004/jnccn.2019.0009 | PMID 30787125 Get It

These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.
Substratification of patients with newly diagnosed standard‐risk multiple myeloma
Binder, Moritz , Lacy, Martha Q. , Hayman, Suzanne R. , Hwa, Yi L. , Zeldenrust, Steven R., Lust, John A., Russell, Stephen J. , Kapoor, Prashant , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Gonsalves, Wilson , Kumar, Shaji K , Binder, Moritz , Russell, Stephen J , Rajkumar, S. Vincent , Ketterling, Rhett P. , Dispenzieri, Angela , Gertz, Morie A. , Leung, Nelson , Go, Ronald S. , Gonsalves, Wilson I.

Mayo Clinic

British Journal of Haematology | February 15, 2019 | Volume: 185 | Issue: 2 | Pages: 254-260

10.1111/bjh.15800 | PMID 30768679 Get It

SummaryDespite the absence of high‐risk cytogenetics and lower International Staging System (ISS) stages, a subset of patients with multiple myeloma (MM) experience poor overall survival (OS). We studied 1461 patients with newly diagnosed MM to identify patient and disease characteristics that predict a high‐risk phenotype among standard‐risk patients. Fifty‐six percent of all patients presented with standard‐risk disease. Among them, advanced age, extremes of body mass index, non‐hyperdiploid karyotype and abnormal lymphocyte counts were associated with worse OS. Standard‐risk patients with 0–1 of these adverse factors (hazard ratio [HR] 0·32, 95% confidence interval [CI] 0·24–0·43, P < 0·001) and 2 adverse factors (HR 0·54, 95% CI 0·41–0·72, P < 0·001) experienced better OS than high‐risk patients. Two or more adverse factors were present in 17% of standard‐risk patients and were associated with OS comparable to high‐risk patients (HR 0·91, 95% CI 0·67–1·24, P = 0·548). Predictive power among standard‐risk patients was improved using score groups compared to ISS stages. Patients with standard‐risk MM are a heterogeneous group with one in six patients experiencing OS comparable to high‐risk disease. Patients at risk can be identified using readily available patient and disease characteristics. These findings emphasize the importance of accurate risk stratification and help explain part of the heterogeneity observed in clinical practice.
Spleen Tyrosine Kinase–Mediated Autophagy Is Required for Epithelial–Mesenchymal Plasticity and Metastasis in Breast Cancer
Shinde, Aparna , Hardy, Shana D., Akhand, Saeed Salehin , Anderson, Joshua C. , Khodadadi, Ryan B. , Brown, Wells S. , George, Jason T. , Liu, Sheng , Wan, Jun , Levine, Herbert , Krusemark, Casey J. , Wendt, Michael K. , Anderson, Joshua C , Khodadadi, Ryan B , Willey, Christopher D , Wendt, Michael K , Wan, Jun , Kim, Dong Wook , Jolly, Mohit Kumar , Wang, Wen‐Hung , Geahlen, Robert L.

Mayo Clinic

Cancer Research | February 7, 2019 | Volume: 79 | Issue: 8 | Pages: 1831-1843

10.1158/0008-5472.can-18-2636 | PMID 30733195 Get It

Abstract The ability of breast cancer cells to transiently transition between epithelial and mesenchymal states contributes to their metastatic potential. Therefore, driving tumor cells into a stable mesenchymal state, as opposed to complete tumor cell eradication, presents an opportunity to pharmacologically limit disease progression by promoting an asymptomatic state of dormancy. Here, we compare a reversible model of epithelial–mesenchymal transition (EMT) induced by TGFβ to a stable mesenchymal phenotype induced by chronic exposure to the ErbB kinase inhibitor lapatinib. Only cells capable of returning to an epithelial phenotype resulted in skeletal metastasis. Gene expression analyses of the two mesenchymal states indicated similar transition expression profiles. A potently downregulated gene in both datasets was spleen tyrosine kinase (SYK). In contrast to this similar diminution in mRNA, kinome analyses using a peptide array and DNA-conjugated peptide substrates showed a robust increase in SYK activity upon TGFβ-induced EMT only. SYK was present in cytoplasmic RNA processing depots known as P-bodies formed during the onset of EMT, and SYK activity was required for autophagy-mediated clearance of P-bodies during mesenchymal–epithelial transition (MET). Genetic knockout of autophagy-related 7 (ATG7) or pharmacologic inhibition of SYK activity with fostamatinib, a clinically approved inhibitor of SYK, prevented P-body clearance and MET, inhibiting metastatic tumor outgrowth. Overall, this study suggests assessment of SYK activity as a biomarker for metastatic disease and the use of fostamatinib as a means to stabilize the latency of disseminated tumor cells. Significance: These findings present inhibition of spleen tyrosine kinase as a therapeutic option to limit breast cancer metastasis by promoting systemic tumor dormancy. See related commentary by Farrington and Narla, p. 1756
Precision medicine in multiple myeloma: are we there yet?
Auclair, Daniel , Kumar, Shaji , Lonial, Sagar , Anderson, Kenneth C.

Mayo Clinic

Expert Review of Precision Medicine and Drug Development | February 7, 2019 | Volume: 4 | Issue: 2 | Pages: 51-53

10.1080/23808993.2019.1578172 Get It